Insmed Inc (NAS:INSM)
$ 75.19 -3.63 (-4.6%) Market Cap: 12.92 Bil Enterprise Value: 13.52 Bil PE Ratio: 0 PB Ratio: 327.00 GF Score: 63/100

Insmed Inc at Nasdaq Investor Conference Transcript

Dec 04, 2019 / 09:15AM GMT
Release Date Price: $23.36 (+1.70%)
Unidentified Speaker Nasdaq;Company Representative

It is our next speaker Rodger Adsett, Chief Operating Officer of Insmed. Roger.

Roger Adsett
Ismed - Chief Operating Officer

Great. Good morning everyone. Thank you very much. My name is Roger Adsett. I'm the chief operating officer at Insmed and I'm very pleased to be here today representing the company.

Let me remind you that today's presentation will include Forward-looking statements and please refer to our filings for the SEC, which are available through the SEC website. Insmed is a global biopharmaceutical company with a focus on helping patients with serious and rare diseases. We look to make a meaningful impact on the lives of patients through our medicines.

We focused on four key strategic priorities for 2019, first continued execution of the U.S. launch of Arikayce. Our first commercial product, Arikayce was approved in September 2018 for the treatment of refractory mycobacterium avium complex or MAC, lung disease in adult patients with limited or no treatment options. Our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot